High-Intensity Interval or Concurrent Exercise on Oxidative Stress and Inflammation in Obese Women

What this trial studies

Introduction: Menopause is associated with body composition change, an increase in the cardio-metabolic risk factor for oxidative stress. Nevertheless, it has been suggested that regular physical training is an effective non-pharmacological intervention to reduce oxidative stress and cardio-metabolic disorders in menopausal individuals. Therefore, the present study was conducted to compare the effects of twelve weeks of high-intensity interval training (HIIT) and concurrent (Conc) and on body composition, cardio-metabolic indices and oxidative stress in sedentary obese postmenopausal women. Materials and methods: Forty-five menopausal obese women voluntarily participated and were randomly assigned into three groups: a) HIIT (6-12×60s of high intensity training (85-95% HRMax) and then running for 60 seconds with low intensity (55-60% HRMax)), b) concurrent endurance (performed on training with 55-75% HRMax) and strength training (including two sets in eight exercise stations with 55-75% 1RM)) and c) control group.

Conditions in scope

• Women Veterans
• Obese Women
• Postmenopausal
• Sedentary Lifestlye

Interventions

• High-Intensity Interval (Behavioral) — HIIT consisted of alternating high- (90-95 % HR_max) and low-intensity (55-60 % HR_max) aerobic bouts
• concurrent training (Behavioral) — combined aerobic and resistance exercises
• Control Group (Behavioral) — usual daily routines

Who can join

Women only · Ages 50 Years to 65 Years

Inclusion criteria

• Women with at least 12 months of amenorrhea.
• Physical abilities with the capacity to exercise safely as determined by a medical evaluation.
• Women in a sedentary state, defined as performing \<150 minutes of moderate to vigorous physical activity per week during the previous year.
• BMI \>25 and ≤40 kg/ m2

Exclusion criteria

• hormone replacement therapy
• smoking.
• diagnosed cardiovascular, renal, or hepatic disease, uncontrolled hypertension, or any musculoskeletal limitation precluding exercise participation

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

Status & timeline

• Overall status: Completed
• Study type: Interventional
• Phase: N/A
• Start date: 2025-09-02
• Primary completion: 2025-11-20
• Last update posted: 2025-12-31
• First posted: 2025-12-24

Sponsor & contact

Lead sponsor: University of Valladolid (Other)

Collaborators: Sanidad de Castilla y León, Ministerio de Ciencia e Innovación, Spain, Fundación General Universidad de Valladolid

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

• Concentration Malondialdehyde (MDA) (nmol/mL) (first day of study and after 80 days of exercise training program (end of study))
  Malondialdehyde (MDA) is a highly reactive compound and a key biomarker for oxidative stress, formed primarily from the breakdown (peroxidation) of polyunsaturated fatty acids in cell membranes, indicating cellular damage
• Serum Total Antioxidant Capacity (TAC) (first day of study and after 80 days of exercise training program (end of study))
  Serum Total Antioxidant Capacity (TAC) measures the overall ability of antioxidants in your blood (serum) to neutralize harmful free radicals, reflecting your body's defense against oxidative stress, a key factor in aging and diseases
• Concentration Monocyte Chemoattractant Protein-1 (MCP-1) (pg/mL) (first day of study and after 80 days of exercise training program (end of study))
  Monocyte Chemoattractant Protein-1 (MCP-1), also known as CCL2, is a vital CC chemokine that acts as a powerful signal, attracting monocytes, macrophages, and T cells to sites of inflammation, infection, and tissue injury in the body, playing a key role in innate immunity and various inflammatory diseases

Related ClearedRx care

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.